Compare Icl Group Ltd (ICL) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Icl Group Ltd trades at $4.99 (market cap $6.38B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Icl Group Ltd is far larger — about 6.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Icl Group Ltd pays a 4.13% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ICL | MRVI | |
|---|---|---|
Market Cap | $6.38B | $972.90M |
Volume | 1,104,238 | 4,325,710 |
Sector | Basic Materials | Health |
52-Week High | $6.80 | $9.00 |
52-Week Low | $4.80 | $2.83 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $9.02B | $1.08B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $4.99, up 1.01% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating expectations, and maintains a dividend of $0.06. Revenue for 2025 was $7.15B with a net income margin of 3.95%. Valuation metrics show a P/E of 20.75 and P/B of 1.05, while analyst consensus is a Hold with a $6.08 price target.
ICL faces headwinds from fertilizer industry challenges but shows earnings resilience. The stock offers a moderate upside to the consensus target, supported by cost-transformation plans. Risks include input cost pressures and competitive dynamics. Institutional interest is evident with Amundi increasing its stake by 49.7% in Q1 2026.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
